Recognizing the subtle early signs of X-linked hypophosphatemia (XLH), a rare genetic disorder affecting bone development, is crucial for timely intervention and improved outcomes for children, according to pediatric experts. The condition, characterized by phosphate wasting in the kidneys, often presents with symptoms that can be easily overlooked in routine pediatric care, leading to delayed diagnosis and potential long-term complications. Early identification of XLH is becoming increasingly important as new treatments emerge, offering the potential to significantly improve growth and skeletal health in affected individuals.
Jill Simmons, MD, has been highlighting the need for increased awareness of XLH among pediatricians. The disorder impacts bone mineralization, leading to rickets – softening and weakening of the bones – in children. While traditionally managed with phosphate supplements and vitamin D analogs, recent advancements, including the development of burosumab, a medication targeting fibroblast growth factor 23 (FGF23), are changing the treatment landscape. However, the effectiveness of these newer therapies is maximized when initiated early in life.
Understanding X-linked Hypophosphatemia
X-linked hypophosphatemia (XLH) is a genetic condition caused by mutations in the PHEX gene, which regulates phosphate levels in the body. As detailed in research published in the Journal of Clinical Endocrinology & Metabolism, the primary issue is renal phosphate wasting, resulting in low phosphate levels in the blood. This, in turn, leads to impaired bone mineralization and the development of rickets. The condition is X-linked dominant, meaning it affects males more severely, but females can also be affected, though often with milder symptoms.
Symptoms of XLH can vary, but often include bowed legs, knock-knees and short stature. Dental problems, such as abscesses and premature loss of teeth, are also common. However, these symptoms can be subtle, especially in the early stages, and may be mistaken for other conditions. The condition is considered the most common heritable form of rickets and osteomalacia.
The Importance of Early Diagnosis
The challenge lies in recognizing XLH before significant skeletal abnormalities develop. Clinicians should be particularly vigilant in children with a family history of the condition or those presenting with unexplained short stature, bone pain, or dental issues. Recent studies emphasize that early intervention is key to maximizing growth potential and preventing long-term complications.
Traditionally, treatment focused on phosphate supplementation and vitamin D analogs. While these therapies can improve growth, they require careful monitoring to avoid hypercalcemia (high calcium levels) and other side effects. The advent of burosumab, which directly addresses the underlying cause of the phosphate wasting by targeting FGF23, has offered a new treatment option. However, research suggests that combining burosumab with recombinant human growth hormone (rhGH) may yield even better results, particularly in children with significant growth deficits. A study found that children treated with burosumab alone showed minimal change in height standard deviation score (SDS) after one year, while those receiving both burosumab and rhGH continued to experience height gain.
Navigating New Treatment Options
The introduction of burosumab has complicated the treatment approach for XLH. While the medication effectively normalizes phosphate levels and reduces FGF23, its impact on growth alone may be limited. The study mentioned above suggests that combining burosumab with rhGH can lead to improved growth outcomes. However, more research is needed to determine the optimal dosage and duration of combined therapy.
The decision to use rhGH in conjunction with burosumab should be individualized, taking into account the child’s age, severity of the condition, and response to treatment. Regular monitoring of phosphate, calcium, and vitamin D levels is essential to ensure safety and efficacy. Clinicians must also be aware of the potential side effects of both medications.
What Clinicians Should Look For
Simmons and other experts emphasize that a high index of suspicion is crucial. Clinicians should consider XLH in any child presenting with:
- Unexplained bowed legs or knock-knees
- Short stature, disproportionately short for their age
- Dental abnormalities, such as abscesses or premature tooth loss
- Bone pain or tenderness
- Family history of XLH or related bone disorders
Early diagnosis typically involves blood tests to assess phosphate, calcium, vitamin D, and FGF23 levels. Genetic testing can confirm the diagnosis by identifying mutations in the PHEX gene.
The landscape of XLH treatment is evolving rapidly. Continued research is needed to optimize treatment strategies and improve the long-term outcomes for affected children. Raising awareness among pediatricians and promoting early diagnosis are essential steps in ensuring that children with XLH receive the care they need to thrive.
Disclaimer: This article provides general information about X-linked hypophosphatemia and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
The next major checkpoint in XLH research will be the ongoing analysis of long-term outcomes from patients receiving burosumab and combined burosumab/rhGH therapies, expected to be presented at the Pediatric Endocrine Society meeting in Spring 2026. Share this information with your network and join the conversation about improving care for children with rare genetic disorders.
